NCT05824585View on ClinicalTrials.gov

DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

230

Participants

Timeline

Start Date

May 15, 2023

Primary Completion Date

April 30, 2027

Study Completion Date

October 30, 2027

Conditions
Lymphoma, Non-Hodgkin
Interventions
DRUG

DZD8586

DZD8586 treatment starting from 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD8586.

Trial Locations (5)

10065

NOT_YET_RECRUITING

Research site, New York

Unknown

RECRUITING

Research site, Albury

NOT_YET_RECRUITING

Research site, Ballarat

RECRUITING

Research site, Melbourne

RECRUITING

Research site, Perth

Sponsors
All Listed Sponsors
lead

Dizal Pharmaceuticals

INDUSTRY

NCT05824585 - DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter